Diabetes mellitus (DM) is the single most common cause of erectile dysfunction (ED) seen in clinical practice. Evaluation of penile arterial insufficiency in diabetic patients currently entails expensive and invasive testing. We assessed the diagnostic value of certain peripheral and cavernous blood markers as predictors of penile arterial insufficiency in diabetic men with ED. This study was conducted on a total of 51 subjects in three groups: 26 impotent diabetics, 15 psychogenic impotent men and 10 normal age matched control males. All subjects underwent standard ED evaluation including estimation of postprandial blood sugar and serum lipid profile. Peripheral venous levels of nitric oxide (NO), lipoprotein(a) (LP(a)), malondialdehyde (MDA) and glycosylated hemoglobin (HbA1c) were obtained in all subjects. Patients in the two impotent groups underwent additional measurement of NO, LP(a) and MDA levels in cavernous blood. They also underwent intracavernosal injection (ICI) of a trimix (papaverine, prostaglandin E1 and phentolamine mixture) and pharmaco-penile duplex ultrasonography (PPDU). Compared to patients in the psychogenic group, diabetic men had significantly lower erectile response to ICI (Po0.001), lower peak systolic velocity (PSV) (Po0.001), and smaller increase in cavernosal artery diameter (CAD) (Po0.001). Peripheral and cavernous levels of both LP(a) and MDA were higher in the diabetic group as compared to the psychogenic ED group (Po0.001), while the values of peripheral venous and cavernous NO were lower (Po0.001) in the diabetic men. Comparison of biochemical marker assays with the PPDU results showed a significant negative correlation between both venous and cavernous LP(a) and MDA levels on the one hand, and PSV, and the percentage of CAD increase on the other. At the same time, peripheral and cavernous NO levels had a significant positive correlation with the same parameters. Lipoprotein(a), MDA and NO levels were better predictors of low PSV than HbA1c, cholesterol or triglyceride levels. The finding of high levels of LP(a) and MDA with low levels of NO in the peripheral and cavernous venous blood of diabetic men with ED correlates strongly with severity of ED as measured by PPDU. This provides a rationale for further studies of biochemical markers as a surrogate for traditional invasive testing in the diagnosis of penile arterial insufficiency.
Introduction
Erectile dysfunction (ED) is frequently associated with diabetes mellitus (DM).
1,2 Diabetic impotence is thought to be mainly due to a combination of vascular and neurogenic changes. 3 It is becoming increasingly evident that endothelial and smooth muscle functions are disordered in diabetes and these may be the most important factor in the development of ED in a majority of diabetic men. 4, 5 Nitric oxide (NO) has been the subject of intense interest since its biological description in 1987. 6 It is synthesized from L-arginine by a family of nitric oxide synthetases (NOS). The release of NO by cholinergic and non-cholinergic nerves appears to be the major contribution of the parasympathetic nervous system during erection. Nitric oxide is now understood to be the most significant mediator of vascular smooth muscle relaxation responsible for engorgement of erectile tissue in men. [7] [8] [9] Hypercholesterolemia in diabetic patients is a contributing factor in atherosclerosis and also leads to an increased risk of impotence.
2 Lipoprotein(a) (LP(a)) is a glycoprotein component of low-density lipoprotein (LDL) which is attached to apolipoprotein B-100. Lipoprotein(a) may enhance fibrous plaque formation in atherosclerotic lesions, and its elevation has been suggested to be an independent risk factor for atherosclerosis. 10 Oxidative stress is believed to affect the development of diabetic-associated vasculopathy, endothelial dysfunction and neuropathy within erectile tissue. 11, 12 Malondialdehyde (MDA) is a known byproduct of reactive oxygen species (ROS) metabolism. 13 Griesmacher et al.
14 observed a significant rise in MDA in diabetic patients. With increased peroxidation and reduced antioxidant reserve in diabetes, oxidative stress may play an important role in the pathogenesis of diabetic vascular complications. 13 The aim of this work was to study the plasma levels of NO, LP(a) and MDA in peripheral and cavernous blood of diabetic ED patients, and to correlate these biochemical parameters with other invasive procedures for the diagnosis of penile arterial insufficiency.
Subjects and methods

Subject groups
This study included 26 type II diabetic men with ED, with ages ranging from 33 to 60 years (mean 44.975.9 years) and a mean duration since diagnosis of diabetes of 3.3 years. Of the 26 patients, 12 were on insulin therapy. Fifteen impotent patients with psychogenic etiology with ages ranging from 32 to 59 years (mean 42.878.4 years) were enrolled for comparison. Finally, 10 normal potent men with the same age range (mean 40.375.1 years) were taken as a healthy control group. Informed consent was obtained from all patients.
We excluded diabetic patients with macro-vascular complications (coronary artery disease, hypertension, transient ischemic attacks, strokes, peripheral ischemia) and overt peripheral neuropathy. We also excluded patients using antihypertensive drugs, systemic steroids, histamine-2 blockers and antidepressants. All cigarette smokers and alcoholics were also excluded.
Intracavernosal injection
Intracavernosal injection (ICI) was carried out for the two impotent groups only. Injections consisted of 0.5 ml of a Trimix solution containing 30 mg/ml of papaverine hydrochloride, 10 mg/ml of prostaglandin E1 and 1 mg/ml of phentolamine. Patients were then observed for 1 h to assess the erectile response by a physician who was blinded to the results of the biochemical assays.
Pharmaco-penile duplex ultrasonography Pharmaco-penile duplex ultrasonography (PPDU) was performed, again, for the two impotent groups only. It included measurements of cavernosal artery diameter (CAD) before and after ICI, peak systolic velocity (PSV) and end diastolic velocity (EDV) using a 7.5 MHz Toshiba SAL 270-A transducer (Toshiba Corp., Japan). Measurements of CAD and blood flow velocities were repeated approximately 2, 5, 10 and 20 min after the injection of Trimix.
Biochemical investigations
Fasting blood samples were taken from the antecubital vein of all impotent patients and all healthy controls. An additional sample was taken from the flaccid penis of impotent diabetic and psychogenic patients only. All blood samples were collected in tubes containing EDTA, centrifuged and plasma was separated and divided into aliquots, which were stored at À201C till assayed. One part of the whole peripheral venous blood was used for the determination of HbA1c by ion exchange resin procedure 15 using kits supplied by Stanbio, USA.
Plasma NO assay involved the conversion of nitrate to nitrite by the enzyme nitrate reductase. The detection of total nitrite was determined as a colored azodye product of the Griess reaction that absorbs visible light using a micro plate reader set at 540 nm. According to the method of Schmidt and Walter, 16 nitrate reductase enzyme was used with nicotinamide adenine dinucleotide (NADH) as cofactor to reduce nitrate to nitrite. This assay was performed using kits supplied by R&D Systems Inc. (Minneapolis, MN, USA).
For the MDA assay, the lipid peroxide content in plasma was determined by measuring the thiobarbituric acid-reactive substances expressed as MDA equivalents (nmol/ml) as described by Matsumoto et al. 17 Lipoprotein(a) assay was carried out by immunoprecipitin analysis according to Gries et al. 18 with reagents obtained ready for use from Incstar corp. (Stillwater, MN, USA). Plasma levels of total cholesterol, 19 high-density lipoprotein (HDL) cholesterol 20 and triglycerides 21 were estimated by kits of BioMerieux Lab (France). Plasma LDL cholesterol was calculated according to Friedewald et al.
22
Statistical methods Statistical package of social sciences (SPSS) was used for data management and analysis. Data were The source of the blood sample (peripheral vs cavernous) did not affect the results of the marker assays (Tables 1 and 2 ). The differences in peripheral marker levels observed between diabetic and non-diabetic ED patients remained significant when cavernous blood samples were analyzed ( Table 2) .
Intracavernosal injection results
Intracavernosal injection results are summarized in Table 2 . There was a highly significant increase in PSV in the psychogenic group compared to the Table 2 ). Also, the percentage of CAD increase after trimix injection was higher in the psychogenic than in the diabetic group (94.6718 and 53.0717.8%, respectively, Po0.001, Table 2 ).
Correlation of biochemical markers and ICI results within diabetic group
Within the diabetic group, there was a significant positive correlation between venous LP(a) and the duration of impotence (r ¼ 0.59, Po0.05), and the degree of glycemic control as measured by HgbA1c (r ¼ 0.69). The objective measures of PSV and percent CAD increase after ICI also correlated strongly with LP(a) levels (r ¼ À0.81 and À0.88 for PSV and %CAD, respectively, Po0.05). There were significant correlations between venous NO levels and invasive testing results as well (Table 3 and Figure 1b ). While venous NO levels correlated somewhat weakly with the duration of impotence (r ¼ À0.33), we found a strong positive correlation of NO levels with subjective response to ICI (r ¼ 0.64, Po0.05), PSV (r ¼ 0.75, Po0.05) and percent CAD increase (r ¼ 0.76, Po0.05).
These correlations were not affected by the source of venous blood (peripheral vein vs flaccid penis) ( Table 3) .
Biochemical markers as predictors of arterial insufficiency
Using the definition of PSVo25 cm/s after ICI as diagnostic of arterial insufficiency, 18 of 41 (44%) impotent men were found to have arterial insufficiency. As a surrogate test, LP(a) had a 91% sensitivity and a 78% specificity using a cutoff of 430 mg/dl to predict arterial disease, while MDA was 91% sensitive and 89% specific at a cutoff of 1.7 nmol/ml. HbA1c was less accurate in predicting low PSV with a sensitivity of 91% at HbA1c 47%, but a specificity of only 44%. To compare the various tests in a cutoff independent manner, ROC area under curve were calculated (Table 4) . These show that LP(a) was the best test in predicting Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels MA El-Latif et al arterial insufficiency, and was superior to HbA1c (P ¼ 0.006).
Discussion
Erectile dysfunction is a common pathological development in individuals with DM. 1, 2 It is thought to be mainly due to a combination of vascular and neurogenic changes 3 and is strongly associated with other risk factors of cardiovascular disease.
Lipoprotein(a) levels have been suggested to be an independent risk factor for atherosclerosis, 10 which is, in turn, highly associated with ED. In our study, we found significantly higher levels of LP(a) and total cholesterol in the diabetic group than in both the psychogenic impotent and the healthy control groups, while the difference between the latter two groups was non-significant. The increased levels of LP(a) correlated with poor response to ICI as measured by CAD increase and PSV, in agreement with others. 23 These findings also confirm previous studies suggesting that ED in diabetic patients is associated with impaired penile arterial flow. 7, 24 This can be explained by atherosclerosis of large arteries and microangiopathy of small arteries occurring in DM, 4 and we propose that increased LP(a) may be a marker of these changes.
Development and maintenance of penile erection requires the relaxation of the smooth muscle cells in the cavernous bodies and is essentially mediated by NO. 7, 25 During sexual stimulation, NO is synthesized from L-arginine by nitric oxide synthases of neuronal (nNOS) and endothelial (eNOS) origins. 25, 26 In this study, we found a significant decrease of cavernosal and peripheral NO in diabetic patients, but not in patients with psychogenic ED, in agreement with others. 27 This finding could be due to the presence of advanced glycosylation end-products (AGEs), compounds that are formed as a result of non-enzymatic reaction between glucose and the amino groups of proteins. Advanced glycosylation end-products have been shown to quench NO and result in attenuation of NO-mediated relaxation of cavernosal smooth muscle. 28, 29 More recently, it was shown that eNOS itself is modified by addition of O-GlcNAc residue in a rat model of diabetic ED. 25 As a result, endothelial production of NO in response to shear stress, believed to be necessary for maintaining erections, was impaired. 25 Another possible mechanism of reduced NO in diabetics is competition for the Arginine substrate be Arginase II, which has been shown to be upregulated in the corpus cavernosum of diabetics. 8, 30 Increased oxidative stress via the production of ROS has been reported in the diabetic state. 13, 30 Our studies confirm that increased oxidative stress, as measured by MDA levels, correlates with poor erectile response in human subjects. In addition, our study agrees with Sozmen et al., 31 who reported that poor glycemic control is strongly associated with an increase in free radicals and diabetic complications, and extends their findings to ED. Others have studied the mechanisms by which oxidative stress could cause ED. 12 In a rabbit model of diabetic ED, Khan et al. 32 found that increased levels of superoxide anion in diabetes can divert NO away from the erectogenic pathway through its conversion to peroxynitrite, and that addition of superoxide dismutase enhanced NO-mediated muscle relaxation. 31 Similarly, supplementation with vitamin E, a free radical scavenger, was found to increase PDE5 inhibitor-mediated erection in diabetic rats. 33 The results of our study showed, also, a nonsignificant difference between both peripheral venous and cavernous NO in diabetic patients. The high correlation between cavernosal and venous values of the biochemical markers suggest that these changes are reflective of systemic changes, and are not selective for the cavernosal tissues. 5 In addition, the present studies do not establish that these markers are selective for erectile dysfunction among the general diabetic population, since we did not include potent diabetic patients as controls. This was a reasonable approach given the invasive nature of penile arterial testing and cavernosal blood sampling. Still, the markers studied were specific to arterial dysfunction among diabetic men, to a degree not predicted by glycated hemoglobin alone.
So, we can conclude that the finding of high levels of LP(a) and MDA with low levels of NO in peripheral venous blood correlates with the severity of ED as measured by PPDU testing. However, we should caution that these assays are not currently standardized. Therefore, it may be more appropriate to use them as an adjunct, rather than a replacement, to invasive testing at this time. An additional limitation is that we have chosen to apply extensive exclusion criteria, especially smoking and overt cardiovascular disease, in order to avoid potential Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels MA El-Latif et al confounders. One drawback of this approach, however, is the limitation of the ability to generalize the present findings to the entire population of diabetic men with ED. Our findings provide a rationale for future studies of biochemical markers in a wider population of diabetic men with ED.
